drugset / Trial / NCT01380678
Intralesional Bevacizumab Injection on Primary Pterygium
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study is to evaluate that intralesional injection of bevacizumab on primary pterygium can reduce the corneal pterygium area, inflammation, redness and other symptoms.
Timeline
- Start
- 2009-01
- Primary completion
- 2012-12
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bevacizumab | Monoclonal antibody | 2 mg | Other |
| Comparator | Tetrahydrozoline | Small molecule | 0.04 % | Topical |
| Comparator | antazoline | Small molecule | 0.05 % | Topical |